Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma TBPH reported first-quarter 2026 adjusted earnings of 1 cent per share, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago quarter, the company had incurred an adjusted loss of 17 cents per share.Total revenues in the quarter were $17.7 million, ...

Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program.

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the fourth quarter and full year of 2025.

The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Turtle Beach (TBCH) delivered earnings and revenue surprises of -83.53% and -8.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?